On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: XOMA (NASDAQ:XOMA), Celladon (NASDAQ:CLDN), AK Steel Holding (NYSE:AKS), Chimerix (NASDAQ:CMRX)
Formerly on March 11, 2015 XOMA Corp (NASDAQ:XOMA) stated its operational highlights and financial results for the quarter and year ended December 31, 2014.
Advanced all gevokizumab clinical studies, including initiating the Phase 3 EYEGUARD(TM)-US study in U.S. patients with Behcet’s disease uveitis and the Phase 3 study in patients with pyoderma gangrenosum.
Completed enrollment of eight patients in the gevokizumab open-label proof of concept clinical trial in patients with active, non-infectious, anterior scleritis being conducted under Dr. Nida Sen’s leadership at The National Eye Institute (NEI). The study objectives were to evaluate the safety and possible efficacy of gevokizumab in patients with active scleral inflammation at baseline. Although the study is still ongoing, 6 of the 8 study participants had a positive response in the first 16 weeks of gevokizumab treatment, based on a standardized scale. The Company will be working with NEI to design a possible multi-center controlled trial in this difficult to treat condition.
XOMA Corp (NASDAQ:XOMA) fell -3.62%, and closed at $3.99. The stock has the beta value of 3.04, and its volatility for the week is 6.72%, while for the month it is 6.44%. The company has the market capitalization of $463.58 million. The company holds the book value per share of 0.03, whereas cash per share is 0.67. Price to book ratio remained 1.80, while price to sale ratio is 24.53. Analysts mean recommendation for the stock is said to be 1.80 (where 1=Buy, 5=sale).
XOMA Corp (XOMA) discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçets disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
Formerly on March 16, 2015 Celladon Corp (NASDAQ:CLDN) a mrdical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, uncovered that on March 9, 2015 the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 40,000 shares of common stock to three new employees, with two of such grants having a grant date of March 9, 2015 (the “March 9 Grants”) and the third having a grant date of March 11, 2015 (the “March 11 Grant”), with each such grant date corresponding to the employees’ respective hire dates.
Celladon Corp (NASDAQ:CLDN) decreased -3.60%, and closed at $26.28,. The company holds the market capitalization of $612.45M. For the last twelve months, the stock was able to keep return on equity at -88.50%, while return on assets at -51.90%. Its 20-day moving average gained 20.20%, below 50-day moving average of 38.63%, below 200-day moving average of 86.53% from the latest market price of $26.28. The mean recommendation of analysts for this stock is 1.50. (Where 1=Buy, 5=Sale).
Celladon Corp (CLDN) a clinical-stage biotechnology company focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The companys lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart.
On March 19, 2015 AK Steel Holding Corporation (NYSE:AKS) supplied guidance for its first quarter 2015 financial results. AK Steel said that it expects to report a net loss of $0.23 to $0.28 per diluted share of common stock for the first quarter of 2015. AK Steel said that the company’s results of operations for the first quarter of 2015 have been significantly and negatively impacted by lower than expected carbon steel spot market shipments and prices due to unexpectedly high levels of what AK Steel believes are unfairly traded imports.
AK Steel Holding Corporation (NYSE:AKS) declined -3.57%, and closed at $4.05. The company has the market capitalization of $720.03 million. The beta value of the stock is 2.27. On the other hand the stock’s volatility for the week is 5.96%, and for the month is 4.84%. The price to sale ratio is 0.11. Analyst’s mean recommendation regarding this stock is 3.00. (Where 1=Buy, 5=Sale).
AK Steel Holding Corporation (AKS) along with its subsidiary, AK Steel Corporation, produces flat-rolled carbon, stainless and electrical steel, and tubular products in the United States and internationally. It produces flat-rolled value-added carbon steels, including coated, cold-rolled, and hot-rolled carbon steel products; and specialty stainless and electrical steels in sheet and strip forms
Formerly on March 6, 2015 Chimerix Inc (NASDAQ:CMRX) a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, disclosed financial results for the fourth quarter and full year 2014. M. Michelle Berrey, MD, MPH, President and CEO of Chimerix, said, “The past year was one of significant growth and progress for Chimerix. As we look forward in 2015, we are focused on completing enrollment of the SUPPRESS trial of brincidofovir for the prevention of CMV, preparing for its expected NDA filing, and continuing our pre-launch initiatives. We are enrolling patients in our Phase 3 AdVise trial, and we are enthusiastic about our preliminary data that suggest a survival benefit in patients with adenovirus infection who received brincidofovir.
Chimerix Inc (NASDAQ:CMRX)’s shares picked down -3.56%, and closed at $40.61. The stock volatility for the week is 4.50%, while for the month remained 4.46%. The company holds consensus target price of $50.56.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -1.77 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 50.70%.
The mean recommendation of analysts for this stock is 1.70. (Where 1=Buy, 5=Sale).
Chimerix Inc (CMRX) a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
